Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Rating of “Buy” from Analysts

Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $26.00.

A number of equities analysts have commented on the stock. BMO Capital Markets assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Thursday, June 14th. They issued an “outperform” rating and a $21.00 price target on the stock. ValuEngine upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 11th. Finally, Wells Fargo & Co lowered shares of Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th.

In other news, insider Aaron Schuchart sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $9.50, for a total transaction of $57,000.00. Following the transaction, the insider now directly owns 8,400 shares in the company, valued at $79,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 18.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC lifted its position in shares of Aeglea Bio Therapeutics by 20.0% during the second quarter. Nantahala Capital Management LLC now owns 2,213,052 shares of the biotechnology company’s stock worth $23,414,000 after purchasing an additional 368,379 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of Aeglea Bio Therapeutics by 26.9% during the second quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company’s stock worth $19,737,000 after purchasing an additional 396,000 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Aeglea Bio Therapeutics by 1.4% during the second quarter. Jennison Associates LLC now owns 1,525,447 shares of the biotechnology company’s stock worth $16,139,000 after purchasing an additional 20,349 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Aeglea Bio Therapeutics by 22.0% during the second quarter. Baker BROS. Advisors LP now owns 1,387,872 shares of the biotechnology company’s stock worth $14,684,000 after purchasing an additional 250,000 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Aeglea Bio Therapeutics by 3,257.3% during the second quarter. BlackRock Inc. now owns 822,505 shares of the biotechnology company’s stock worth $8,703,000 after purchasing an additional 798,006 shares in the last quarter. Institutional investors own 66.50% of the company’s stock.

NASDAQ:AGLE opened at $9.57 on Friday. The stock has a market capitalization of $204.70 million, a price-to-earnings ratio of -5.32 and a beta of 0.03. Aeglea Bio Therapeutics has a 12 month low of $3.75 and a 12 month high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.10). The firm had revenue of $2.38 million during the quarter. Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. equities research analysts predict that Aeglea Bio Therapeutics will post -1.8 EPS for the current year.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: What is the NASDAQ Stock Market?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply